The pharmacokinetics of α-human atrial natriuretic polypeptide in healthy subjects

K. Nakao; A. Sugawara; N. Morii; M. Sakamoto; T. Yamada; H. Itoh; S. Shiono; Y. Saito; K. Nishimura; T. Ban; K. Kangawa; H. Matsuo; H. Imura

doi:10.1007/BF00870995

The pharmacokinetics of α-human atrial natriuretic polypeptide in healthy subjects

K. Nakao, A. Sugawara, N. Morii, M. Sakamoto, T. Yamada, H. Itoh, S. Shiono, Y. Saito, K. Nishimura, T. Ban, K. Kangawa, H. Matsuo, H. Imura

Research output: Contribution to journal › Article › peer-review

90 Citations (Scopus)

Abstract

We have analysed the pharmacokinetics of α-human atrial natriuretic polypeptide (α-hANP) in healthy subjects, using a two-compartment open model following bolus intravenous injection. The plasma half-times for the fast and slow components were 1.7±0.07 min and 13.3±1.69 min respectively. V₁ (the volume of the central compartment), V_z (volume of distribution) and V_ss (volume of distribution at steady-state) were 5370±855 ml (89.5±14.3 ml·kg^-1), 32000±4620 ml (533±77.0 ml·kg^-1), and 11900±1530 ml (198±25.5 ml·kg^-1) respectively. The mean plasma clearance was 1520±121 ml·min^-1 (25.4±2.0 ml·min^-1·kg^-1.

Original language	English
Pages (from-to)	101-103
Number of pages	3
Journal	European Journal of Clinical Pharmacology
Volume	31
Issue number	1
DOIs	https://doi.org/10.1007/BF00870995
Publication status	Published - 1986 Jan 1
Externally published	Yes

Keywords

atrial natriuretic polypeptide
pharmacokinetics
radioimmunassay
α-hANP

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF00870995

Cite this

@article{5cbf00193b1c4d5e8c3eea9449be6f79,

title = "The pharmacokinetics of α-human atrial natriuretic polypeptide in healthy subjects",

abstract = "We have analysed the pharmacokinetics of α-human atrial natriuretic polypeptide (α-hANP) in healthy subjects, using a two-compartment open model following bolus intravenous injection. The plasma half-times for the fast and slow components were 1.7±0.07 min and 13.3±1.69 min respectively. V1 (the volume of the central compartment), Vz (volume of distribution) and Vss (volume of distribution at steady-state) were 5370±855 ml (89.5±14.3 ml·kg-1), 32000±4620 ml (533±77.0 ml·kg-1), and 11900±1530 ml (198±25.5 ml·kg-1) respectively. The mean plasma clearance was 1520±121 ml·min-1 (25.4±2.0 ml·min-1·kg-1.",

keywords = "atrial natriuretic polypeptide, pharmacokinetics, radioimmunassay, α-hANP",

author = "K. Nakao and A. Sugawara and N. Morii and M. Sakamoto and T. Yamada and H. Itoh and S. Shiono and Y. Saito and K. Nishimura and T. Ban and K. Kangawa and H. Matsuo and H. Imura",

year = "1986",

month = jan,

day = "1",

doi = "10.1007/BF00870995",

language = "English",

volume = "31",

pages = "101--103",

journal = "European Journal of Clinical Pharmacology",

issn = "0031-6970",

publisher = "Springer Verlag",

number = "1",

}

TY - JOUR

T1 - The pharmacokinetics of α-human atrial natriuretic polypeptide in healthy subjects

AU - Nakao, K.

AU - Sugawara, A.

AU - Morii, N.

AU - Sakamoto, M.

AU - Yamada, T.

AU - Itoh, H.

AU - Shiono, S.

AU - Saito, Y.

AU - Nishimura, K.

AU - Ban, T.

AU - Kangawa, K.

AU - Matsuo, H.

AU - Imura, H.

PY - 1986/1/1

Y1 - 1986/1/1

N2 - We have analysed the pharmacokinetics of α-human atrial natriuretic polypeptide (α-hANP) in healthy subjects, using a two-compartment open model following bolus intravenous injection. The plasma half-times for the fast and slow components were 1.7±0.07 min and 13.3±1.69 min respectively. V1 (the volume of the central compartment), Vz (volume of distribution) and Vss (volume of distribution at steady-state) were 5370±855 ml (89.5±14.3 ml·kg-1), 32000±4620 ml (533±77.0 ml·kg-1), and 11900±1530 ml (198±25.5 ml·kg-1) respectively. The mean plasma clearance was 1520±121 ml·min-1 (25.4±2.0 ml·min-1·kg-1.

AB - We have analysed the pharmacokinetics of α-human atrial natriuretic polypeptide (α-hANP) in healthy subjects, using a two-compartment open model following bolus intravenous injection. The plasma half-times for the fast and slow components were 1.7±0.07 min and 13.3±1.69 min respectively. V1 (the volume of the central compartment), Vz (volume of distribution) and Vss (volume of distribution at steady-state) were 5370±855 ml (89.5±14.3 ml·kg-1), 32000±4620 ml (533±77.0 ml·kg-1), and 11900±1530 ml (198±25.5 ml·kg-1) respectively. The mean plasma clearance was 1520±121 ml·min-1 (25.4±2.0 ml·min-1·kg-1.

KW - atrial natriuretic polypeptide

KW - pharmacokinetics

KW - radioimmunassay

KW - α-hANP

UR - http://www.scopus.com/inward/record.url?scp=0022456659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022456659&partnerID=8YFLogxK

U2 - 10.1007/BF00870995

DO - 10.1007/BF00870995

M3 - Article

C2 - 2946587

AN - SCOPUS:0022456659

SN - 0031-6970

VL - 31

SP - 101

EP - 103

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

IS - 1

ER -

The pharmacokinetics of α-human atrial natriuretic polypeptide in healthy subjects

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this